Vancouver, B.C. – TheNewswire - Oct 8, 2024 – Solarvest BioEnergy Inc. (“Solarvest”, or the “Company”) (TSXV:SVS.H), is pleased to announce that the buyer of the Company’s property located at 3867 Greenfield Rd, Summerville, PEI, upon successful closing of the sale has agreed to lease space to the Company in order that the Company may continue research and development of its products and technology.

 

In addition, the Company intends to introduce its Organic Omega-3 products in the USA. Initially, the Company will focus on marketing its dried powder currently in inventory in Germany followed by the introduction and marketing of the capsule. The Company will review its options to commercialize its products and will actively pursue partnerships in the USA to assist with the development of its Organic Omega-3 products.

 

The Company further plans to review its Bone Morphogenetic Protein(s) (BMP) technology. In 2015, Solarvest announced its patented Algal Platform to efficiently produce complex bioactive therapeutic compounds.

 

• Micro-algae harbour no known human pathogens, unlike the currently utilized human, bacterial and animal cells lines  

• Algae are capable of high quality, volume production of active proteins 

• Algae can be grown in sterile bioreactors under controlled conditions 

  

Solarvest’s Algal Platform has many advantages as compared to current industry processes, which utilize E.coli or yeast in the production and can cost millions of dollars per gram of bioactive compound. The Company’s Algal Platform breakthrough could substantially reduce the cost of production, with the potential to increase the economical access to hundreds of products for human and animal health.

 

Previously, a proof of concept study required Solarvest’s Algal Platform to produce BMP and was completed using experts at the University of Prince Edward Island. The goal of the study was to determine if the algae-produced protein would be active and induce osteogenesis in undifferentiated stem cells. The successful result, in conjunction with previous positive results with other complex proteins, confirms that Solarvest’s Algal Platform is capable of producing active recombinant proteins. In the case of human recombinant BMP proteins, Solarvest successfully produced a complex, soluble, properly folded and dimerized protein(s). A dimer is two individual proteins units joined together and BMP is only active when presented as a dimer with the proper three dimensional configuration.

 

Solarvest intends to continue with BMP proof of concept and explore avenues to commercialize BMP for veterinary and human applications and will seek supportive partnerships with companies that are active in this and other bioactive protein markets.

 

The Company is also pleased to announce that Mr. Paul Lipoth a long-term shareholder of the company has joined the board effective immediately. Mr Lipoth brings years of experience in doing business with TSX Venture companies and will assist with guiding Solarvest through its next phase of development.

 

A review of the Company’s patents is currently under way and a revised business plan is being worked on. This Board and management team are committed to creating value for shareholders. The Company will provide further updates as they become available.

  

ABOUT SOLARVEST

 

Solarvest is a Canadian algal biologic research company with several unique patents in organic ingredient production with global commercial product applications. With a commitment to innovation and a dedication to harnessing the power of nature, Solarvest is poised to transform the landscape of healthcare with its proprietary organic solutions.

 

For more information, please visit www.solarvest.com

 

For further information contact:

Grant Larsen

Chief Executive Officer

Phone: 1.647.992.6487

Email: invest@solarvest.ca

Forward-Looking Statement

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.